Suppr超能文献

稳定期慢性阻塞性肺疾病患者雾化器维持治疗:重新评估的必要性。

Maintenance Therapy with Nebulizers in Patients with Stable COPD: Need for Reevaluation.

作者信息

Terry Paul D, Dhand Rajiv

机构信息

Department of Medicine, Graduate School of Medicine, University of Tennessee Medical Center, Knoxville, TN, USA.

出版信息

Pulm Ther. 2020 Dec;6(2):177-192. doi: 10.1007/s41030-020-00120-x. Epub 2020 May 20.

Abstract

Patients with stable COPD rely heavily on inhaled bronchodilators and corticosteroids to control symptoms, maximize quality of life, and avoid exacerbations and costly hospitalizations. These drugs are typically delivered by hand-held inhalers or nebulizers. The majority of patients are prescribed inhalers due to their perceived convenience, portability, and lower cost, relative to nebulizers. Unfortunately, poor inhaler technique compromises symptom relief in most of these patients. In contrast to one or two puffs through an inhaler, nebulizers deliver a drug over many breaths, through tidal breathing, and hence are more forgiving to poor inhalation technique. To what extent susceptibility to errors in their use may influence the relative effectiveness of these two types of inhalation device has received little attention in COPD research. In 2005, a systematic review of the literature concluded that nebulizers and inhalers are equally effective in patients who are adequately trained to use their inhalation device. This conclusion was based on two small clinical trials that only examined objective measures of lung function. Since then, additional studies have found that maintenance therapy administered by nebulizers could improve patients' reported feelings of symptom relief, quality of life, and satisfaction with treatment, compared to therapy administered by inhalers. Because it has been 15 years since the publication of the systematic review, in this article we summarize the results of studies that compared the effectiveness of inhalers with that of nebulizers in patients with stable COPD and discuss their implications for clinical practice and need for future research.

摘要

稳定期慢性阻塞性肺疾病(COPD)患者严重依赖吸入性支气管扩张剂和皮质类固醇来控制症状、最大化生活质量并避免病情加重和昂贵的住院治疗。这些药物通常通过手持吸入器或雾化器给药。相对于雾化器,大多数患者因吸入器使用方便、便于携带且成本较低而被处方使用吸入器。不幸的是,大多数此类患者吸入器使用技术不佳会影响症状缓解效果。与通过吸入器吸入一到两喷不同,雾化器通过潮式呼吸在多次呼吸过程中给药,因此对不佳的吸入技术更宽容。在COPD研究中,使用这两种吸入装置时易出错的程度对它们相对有效性的影响鲜受关注。2005年,一项文献系统评价得出结论,对于经过充分培训以使用吸入装置的患者,雾化器和吸入器同样有效。这一结论基于两项仅检查肺功能客观指标的小型临床试验。从那时起,更多研究发现,与吸入器给药相比,雾化器进行维持治疗可改善患者报告的症状缓解感受、生活质量和对治疗的满意度。由于该系统评价发表已有15年,在本文中,我们总结了比较吸入器与雾化器在稳定期COPD患者中有效性的研究结果,并讨论其对临床实践的意义以及未来研究的必要性。

相似文献

10
Delivery technology of inhaled therapy for asthma and COPD.哮喘和慢性阻塞性肺疾病吸入疗法的给药技术
Adv Pharmacol. 2023;98:273-311. doi: 10.1016/bs.apha.2023.03.001. Epub 2023 Mar 28.

引用本文的文献

4
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.恩塞福林作为一种新型吸入疗法用于 COPD 患者的治疗。
Int J Chron Obstruct Pulmon Dis. 2023 Jul 28;18:1611-1622. doi: 10.2147/COPD.S413436. eCollection 2023.

本文引用的文献

2
Inhalation Therapy for Stable COPD: 20 Years of GOLD Reports.稳定期 COPD 的吸入治疗:GOLD 报告 20 年。
Adv Ther. 2020 May;37(5):1812-1828. doi: 10.1007/s12325-020-01289-y. Epub 2020 Apr 3.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验